1 active not recruiting, 1 recruiting. 1 Phase 2, 1 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 1 | Recruiting 1 |
| Phase 3 | 1 | Active not recruiting 1 |
Follow Isatuximab SC: new trials by email Literature Review of Isatuximab SC trials Research Report on Isatuximab SC
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| ELISA in Relapsed/Refractory MM elranatamab, Isatuximab SC, Isatuximab SC-OBDS - Relapsed Refractory Multiple Myeloma (RRMM), Relapsed Refractory Multiple Myeloma | Phase 2 | Recruiting | Massachusetts General Hospital | 30 | 2025-08-14 | 2026-09-16 |
| SC Versus IV Isatuximab in Combination With Pomalidomide and Dexamethasone in RRMM Isatuximab IV, Isatuximab SC, Dexamethasone - Plasma Cell Myeloma Recurrent | Phase 3 | Active not recruiting | Sanofi | 531 | 2022-06-23 | 2026-09-02 |
Multiple Myeloma (1) · Recurrence (1)
Massachusetts General Hospital (1) · Sanofi (1)
United States (2) · Argentina (1) · Australia (1) · Brazil (1) · Canada (1) · Chile (1) · China (1) · Czechia (1) · France (1) · Germany (1) · Greece (1) · Hungary (1) · Italy (1) · Japan (1) · Norway (1)
Noopur Raje, MD (1)
2023 (1)